Table 2.
Quality indicators during pre- and post-implementation of consensus pathway for managing pneumonia in the ICU
| Quality indicator | Number/number evaluable a (%) | P-value | |
|---|---|---|---|
| Pre-implementation (n = 274) | Post-implementation (n = 158) | ||
| QI-1: Diagnostic criteria for HAP, VAP or HCAP met | 247/257 (96.1) | 150/151 (99.3) | 0.06 |
| QI-2a: Respiratory sample obtained before antibiotics | 253/265 (95.5) | 134/141 (95.0) | 0.81 |
| QI-2b: Blood culture obtained before antibiotics | 214/264 (81.1) | 121/141 (85.8) | 0.23 |
| QI-3: Empiric therapy compliant with ATS/IDSA guidelines [1]b | 79/257 (30.7) | 66/151 (43.7) | 0.01 |
| QI-4: Short-course therapy performed | 5/20 (25.0) | 9/17 (52.9) | 0.10 |
| QI-5a: De-escalation possible | 173/266 (65.0) | 96/140 (68.6) | 0.47 |
| QI-5b: De-escalation possible and performed | 56/173 (32.4) | 36/96 (37.5) | 0.40 |
| QI-6: Clinical success at day 14 | 170/250 (68.0) | 89/134 (66.4) | 0.75 |
ATS, American Thoracic Society; HAP, hospital-acquired pneumonia; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; IDSA, Infectious Diseases Society of America; VAP, ventilator-associated pneumonia.
a All patients were not evaluable for every quality indicator. b Empiric therapy compliant with center-specific guidelines: pre- vs post-implementation, 92/257 (35.8%) vs 77/151 (51.0%); P = 0.002.